Blocking the CB1 receptor reduced cholesterol problems and artery disease in mice, even without obesity | Research

The takeaway

The CB1 receptor inverse agonist rimonabant lowered triglycerides by 56%, reduced atherosclerotic lesions by 64%, and improved cholesterol profiles in lean, dyslipidemic mice.

Cardiovascular researchers, pharmacologists, and those interested in the endocannabinoid system and metabolic disease.

64% reduction in atherosclerotic lesion size

What the researchers found

In lean mice with dyslipidemia, 20 weeks of rimonabant treatment reduced VLDL-TG production by 52%, lowered non-HDL-C by 19%, raised HDL-C by 57%, and decreased atherosclerotic lesion size by 64% with reduced severity (28% vs. 56% severe lesions).

Why it matters

This study separated the cardiovascular benefits of endocannabinoid system inhibition from its anti-obesity effects, showing that CB1 blockade can protect against atherosclerosis through direct lipid metabolism improvements.

The numbers in context

Triglycerides: -56%. VLDL-TG production: -52%. Non-HDL-C: -19%. HDL-C: +57%. Atherosclerotic lesion size: -64%. Severe lesions: 28% vs. 56%. Plasma bile acids: +160%.

How the study worked

Female APOE*3-Leiden.CETP transgenic mice (a humanized model of dyslipidemia) were fed a Western-type diet with or without rimonabant (20 mg/kg/day) for up to 20 weeks. Plasma lipids, bile acids, and atherosclerotic lesions in the aortic valve region were measured.

What this study cannot tell us

Animal study in a specialized transgenic mouse model. Rimonabant was pulled from the European market due to psychiatric adverse effects, limiting direct clinical translation. Sex-specific (only female mice).

How to read the evidence

Well-controlled animal study with a humanized mouse model, but requires human validation.

When this study was published

Published in 2021.

The bigger picture

While rimonabant was withdrawn from human use due to psychiatric side effects, these results suggest the endocannabinoid system plays a direct role in lipid metabolism and atherosclerosis beyond its effects on body weight.

Questions still open

Could peripherally restricted CB1 blockers achieve the same cardiovascular benefits without central nervous system side effects? Do these lipid improvements translate to humans?

Common questions

What is rimonabant?

Rimonabant is a CB1 receptor inverse agonist that was briefly marketed for obesity in Europe but withdrawn due to psychiatric side effects including depression and suicidality.

Did the mice need to be overweight for the treatment to work?

No. The mice were lean, suggesting the cardiovascular benefits came from direct effects on lipid metabolism rather than weight loss.

Read the original research

Cannabinoid type 1 receptor inverse agonism attenuates dyslipidemia and atherosclerosis in APOE∗3-Leiden.CETP mice.

Journal of lipid research, 62, 100070

View on PubMed ↗Publisher’s paper ↗

Citation

van Eenige, Robin; Ying, Zhixiong; Tambyrajah, Lauren; Pronk, Amanda C M; Blomberg, Niek; Giera, Martin; Wang, Yanan; Coskun, Tamer; van der Stelt, Mario; Rensen, Patrick C N; Kooijman, Sander. (2021). Cannabinoid type 1 receptor inverse agonism attenuates dyslipidemia and atherosclerosis in APOE∗3-Leiden.CETP mice.. Journal of lipid research, 62, 100070. https://doi.org/10.1016/j.jlr.2021.100070